Achieve Life Sciences Inc

NASDAQ:ACHVUnited States

Achieve Life Sciences, Inc. is a late-stage clinical pharmaceutical company. The Company is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a well-defined, dual-acting mechanism of action that is both agonistic and antagonistic. Cytisinicline is a partial agonist that binds with high affinity to the alpha-4 beta-2, nicotinic acetylcholine receptors in the brain. Through its dual-acting partial agonist/partial antagonist activity, cytisinicline helps reduce nicotine cravings, withdrawal symptoms and reward and satisfaction associated with smoking. It is developing cytisinicline as an aid to smoking cessation and treatment for nicotine addiction to address the limitations of both prescription drugs and of over the counter (OTC) products.

Contact Information

Headquarters

22722 29TH DR. SE, SUITE 100SEATTLE, WA, United States 98021

Phone

425-686-1500

Fax

302-636-5454

Executives

Executive Chairman of the Board

Thomas King

President, Director, Chief Medical Officer

Cindy Jacobs

Chief Executive Officer, Principal Financial Officer, Director

Richard Stewart

Principal Accounting Officer, Senior Director, Accounting Operations

Jerry Wan

Independent Director

Stuart Duty